IRB Study Number 24-287
Status Recruiting
Institute Taussig Cancer Institute
Description
2.1 Primary Objective
To explore potential factors associated with treatment outcomes and adverse effects of ICI therapy.
2.2 Secondary Objective
To describe cellular processes associated with exposure to ICI therapy.
Inclusion Criteria
Confirmed diagnosis of malignancy. (The study will prioritize melanoma, lung or genitourinary malignancies.)
Planned initiation of therapy within 2 weeks of the baseline blood draw of an FDA-approved ICI.
Age ≥ 18 years.
Provide written informed consent for participation.
Exclusion Criteria
Acute leukemia or planned bone marrow transplant.
Planned surgical resection within 3 months.
Previous treatment with immunotherapy within the past 12 months.
